Home Microbiology Reverse Transcriptase inhibitor - HIV inhibitor Tenofovir Disoproxil

research use only

Tenofovir Disoproxil Reverse Transcriptase inhibitor

Cat.No.S5959

Tenofovir Disoproxil (Bis(POC)-PMPA, GS 4331) is a prodrug of tenofovir, which is metabolised intracellularly to its active anabolite tenofovir diphosphate, a competitive inhibitor of HIV-1 reverse transcriptase and terminates the growing DNA chain.
Tenofovir Disoproxil Reverse Transcriptase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 519.44

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S595901 DMSO]100 mg/mL]false]Ethanol]100 mg/mL]false]Water]Insoluble]false Purity: 99.94%
99.94

Chemical Information, Storage & Stability

Molecular Weight 519.44 Formula

C19H30N5O10P

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 201341-05-1 -- Storage of Stock Solutions

Synonyms Bis(POC)-PMPA, GS 4331 Smiles CC(C)OC(=O)OCO[P](=O)(COC(C)C[N]1C=NC2=C(N)N=CN=C12)OCOC(=O)OC(C)C

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (192.51 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Reverse Transcriptase [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05874440 Recruiting
Chronic Hepatitis b Patients
Sohag University
 April 15 2023 --
NCT03576066 Completed
Chronic Hepatitis B
Assembly Biosciences
 June 11 2018 Phase 2
NCT03361956 Completed
Hepatitis B
Janssen Sciences Ireland UC
 February 13 2018 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map